1. Search Result
Search Result
Results for "

Intestinal development

" in MedChemExpress (MCE) Product Catalog:

26

Inhibitors & Agonists

2

Screening Libraries

2

Biochemical Assay Reagents

1

Peptides

8

Natural
Products

9

Isotope-Labeled Compounds

1

Oligonucleotides

Cat. No. Product Name Target Research Areas Chemical Structure
  • HY-101981
    Uridine 5'-monophosphate
    1 Publications Verification

    5'-​Uridylic acid

    Endogenous Metabolite Cholinesterase (ChE) Potassium Channel Apoptosis Cardiovascular Disease Metabolic Disease
    Uridine 5'-monophosphate (5'-Uridylic acid) is an orally active mitochondrial ATP-dependent potassium channel activator that has a protective effect on the heart. Uridine 5'-monophosphate can promote the synthesis of CDP-choline and induce apoptosis in intestinal epithelial cells, which is beneficial for gut development and reduces diarrhea .
    Uridine 5'-monophosphate
  • HY-W013175
    Uridine 5'-monophosphate disodium salt
    1 Publications Verification

    5'-​Uridylic acid disodium salt

    Endogenous Metabolite Cholinesterase (ChE) Potassium Channel Apoptosis Cardiovascular Disease Metabolic Disease
    Uridine 5'-monophosphate (5'-Uridylic acid) disodium salt is an orally active mitochondrial ATP-dependent potassium channel activator that has a protective effect on the heart. Uridine 5'-monophosphate disodium salt can promote the synthesis of CDP-choline and induce apoptosis in intestinal epithelial cells, which is beneficial for gut development and reduces diarrhea .
    Uridine 5'-monophosphate disodium salt
  • HY-101086
    Acetylcholine iodide
    Maximum Cited Publications
    18 Publications Verification

    ACh iodide

    Endogenous Metabolite mAChR Neurological Disease Endocrinology
    Acetylcholine iodide is a muscarinic receptor modulator. Acetylcholine iodide specifically binds to muscarinic receptors, inhibits sodium absorption, and induces chloride secretion. Acetylcholine iodide changes intestinal ion transport, enhances intestinal secretory function, induces or maintains mammary gland development and lactation. Acetylcholine iodide can be used for intestinal ion transport regulation and mammary gland physiological function research .
    Acetylcholine iodide
  • HY-B2203

    Phosphatase Metabolic Disease
    Monocalcium glycerophosphate is an inhibitor of intestinal alkaline phosphatase F3, and it has anti-cavity properties. Monocalcium glycerophosphate is a source of calcium and phosphorus in total parenteral nutrition solutions, helps prevent the mineralization and development of bones from intravenous nutrition, and maintains the integrity of the intestinal epithelium .
    Monocalcium glycerophosphate
  • HY-W750796

    Butanoic acid-13C4 sodium

    Isotope-Labeled Compounds Endogenous Metabolite
    Butyric acid-13C4 sodium (Butanoic acid-13C4 sodium) is a stable isotope labeled compound with the activity of promoting cell proliferation and regulating gene expression. Butyric acid-13C4 sodium can be used in metabolic research and compound development to help scientists gain a deeper understanding of the role of short-chain fatty acids in organisms. Butyric acid-13C4 sodium also plays an important role in nutrition and intestinal health research, especially in the regulation of probiotic function and intestinal microbiota.
    Butyric acid-13C4 sodium
  • HY-101981R

    5'-​Uridylic acid (Standard)

    Reference Standards Endogenous Metabolite Cardiovascular Disease Metabolic Disease
    Uridine 5'-monophosphate (Standard) is the analytical standard of Uridine 5'-monophosphate. This product is intended for research and analytical applications. Uridine 5'-monophosphate (5'-Uridylic acid) is an orally active mitochondrial ATP-dependent potassium channel activator that has a protective effect on the heart. Uridine 5'-monophosphate can promote the synthesis of CDP-choline and induce apoptosis in intestinal epithelial cells, which is beneficial for gut development and reduces diarrhea.
    Uridine 5'-monophosphate (Standard)
  • HY-W019806

    LNFP I

    Endogenous Metabolite CDK Reactive Oxygen Species (ROS) Apoptosis Enterovirus Bacterial Infection Inflammation/Immunology
    Lacto-N-fucopentaose I (LNFPI) is a human milk oligosaccharide (HMO), possessing antiviral and antibacterial activity. Lacto-N-fucopentaose I can reduce capsid protein VP1 to block virus adsorption, promote CDK2 and reduce cyclin E to recover cell cycle S phase block. Lacto-N-fucopentaose I inhibits ROS production and apoptosis in virus-infected cells. Lacto-N-fucopentaose I can also regulate intestinal microbiota to affect immune system development .
    Lacto-N-fucopentaose I
  • HY-N16479

    Insecticide Infection
    Azadirachtin I is an insecticide targeting insect growth and development-related pathways (e.g., ecdysone signaling pathway, chitin synthesis pathway). Azadirachtin I inhibits chitin synthesis and disrupting intestinal function by interfering with the growth and development processes of insect larvae such as molting and pupation, increasing insect mortality and reducing adult fecundity. Azadirachtin I is promising for research of agricultural pests, such as Lepidoptera, Coleoptera .
    Azadirachtin I
  • HY-172212

    Insecticide Reactive Oxygen Species (ROS) Infection
    SDH-IN-23 (Compound B21) is an SDH inhibitor. SDH-IN-23 exhibits excellent nematicidal activity. SDH-IN-23 can inhibit the feeding, reproduction, and embryonic development of nematodes. Meanwhile, SDH-IN-23 exerts a lethal effect on nematodes by triggering oxidative stress, causing intestinal damage, and inhibiting SDH, among other mechanisms .
    SDH-IN-23
  • HY-P10034

    Pss-PT

    Endogenous Metabolite Endocrinology
    Pheromonotropin (Pseudaletia separata) (Pss-PT) is an armyworm (Pseudaletia separata) pheromone with the C-terminal pentapeptide FXPRL-amide. Pheromonotropin (Pseudaletia separata) belongs to the PK/PBAN family and stimulates sex pheromone biosynthesis in moths, mediating feeding (intestinal muscle contraction), development (embryonic diapause, pupal diapause, and pupation), and defense against natural enemy insects wait .
    Pheromonotropin (pseudaletia separata)
  • HY-W013175R

    5'-​Uridylic acid disodium salt (Standard)

    Endogenous Metabolite Cholinesterase (ChE) Reference Standards Potassium Channel Apoptosis Cardiovascular Disease Metabolic Disease
    Uridine 5'-monophosphate (disodium salt) (Standard) is the analytical standard of Uridine 5'-monophosphate (disodium salt). This product is intended for research and analytical applications. Uridine 5'-monophosphate (5'-Uridylic acid) disodium salt is an orally active mitochondrial ATP-dependent potassium channel activator that has a protective effect on the heart. Uridine 5'-monophosphate disodium salt can promote the synthesis of CDP-choline and induce apoptosis in intestinal epithelial cells, which is beneficial for gut development and reduces diarrhea .
    Uridine 5'-monophosphate disodium salt (Standard)
  • HY-101981S

    5'-Uridylic acid-15N2

    Endogenous Metabolite Isotope-Labeled Compounds Cholinesterase (ChE) Potassium Channel Apoptosis Cardiovascular Disease Metabolic Disease
    Uridine 5'-monophosphate- 15N2 (5'-​Uridylic acid- 15N2) is the 15N labeled Uridine 5'-monophosphate (HY-101981). Uridine 5'-monophosphate (5'-Uridylic acid) is an orally active mitochondrial ATP-dependent potassium channel activator that has a protective effect on the heart. Uridine 5'-monophosphate can promote the synthesis of CDP-choline and induce apoptosis in intestinal epithelial cells, which is beneficial for gut development and reduces diarrhea .
    Uridine 5'-monophosphate-15N2
  • HY-101981S2

    5'-​Uridylic acid-d11 dilithium

    Isotope-Labeled Compounds Endogenous Metabolite Apoptosis Potassium Channel Cholinesterase (ChE) Cardiovascular Disease Metabolic Disease
    Uridine 5'-monophosphate-d11 (5'- Uridylic acid-d11) dilithium is deuterium labeled Uridine 5'-monophosphate (HY-101981). Uridine 5'-monophosphate (5'-Uridylic acid) is an orally active mitochondrial ATP-dependent potassium channel activator that has a protective effect on the heart. Uridine 5'-monophosphate can promote the synthesis of CDP-choline and induce apoptosis in intestinal epithelial cells, which is beneficial for gut development and reduces diarrhea .
    Uridine 5'-monophosphate-d11 dilithium
  • HY-101981S5

    5'-​Uridylic acid-15N2 dilithium

    Isotope-Labeled Compounds Endogenous Metabolite Apoptosis Potassium Channel Cholinesterase (ChE) Cardiovascular Disease Metabolic Disease
    Uridine 5'-monophosphate- 15N2 (5'- Uridylic acid- 15N2) dilithium is 15N labeled Uridine 5'-monophosphate (HY-101981). Uridine 5'-monophosphate (5'-Uridylic acid) is an orally active mitochondrial ATP-dependent potassium channel activator that has a protective effect on the heart. Uridine 5'-monophosphate can promote the synthesis of CDP-choline and induce apoptosis in intestinal epithelial cells, which is beneficial for gut development and reduces diarrhea .
    Uridine 5'-monophosphate-15N2 dilithium
  • HY-W013175S2

    5'-​Uridylic acid-13C9,15N2 disodium

    Isotope-Labeled Compounds Endogenous Metabolite Cholinesterase (ChE) Potassium Channel Apoptosis Cardiovascular Disease Metabolic Disease
    Uridine 5'-monophosphate- 13C9, 15N2 disodium is the 13C and 15N labeled Uridine 5'-monophosphate disodium salt (HY-W013175). Uridine 5'-monophosphate (5'-Uridylic acid) disodium salt is an orally active mitochondrial ATP-dependent potassium channel activator that has a protective effect on the heart. Uridine 5'-monophosphate disodium salt can promote the synthesis of CDP-choline and induce apoptosis in intestinal epithelial cells, which is beneficial for gut development and reduces diarrhea .
    Uridine 5'-monophosphate-13C9,15N2 disodium
  • HY-101981S4

    5'-​Uridylic acid-13C9 dilithium

    Isotope-Labeled Compounds Endogenous Metabolite Apoptosis Potassium Channel Cholinesterase (ChE) Cardiovascular Disease Metabolic Disease
    Uridine 5'-monophosphate- 13C9 (5'- Uridylic acid- 13C9) dilithium is 13C-labeled Uridine 5'-monophosphate (HY-101981). Uridine 5'-monophosphate (5'-Uridylic acid) is an orally active mitochondrial ATP-dependent potassium channel activator that has a protective effect on the heart. Uridine 5'-monophosphate can promote the synthesis of CDP-choline and induce apoptosis in intestinal epithelial cells, which is beneficial for gut development and reduces diarrhea .
    Uridine 5'-monophosphate-13C9 dilithium
  • HY-B1036

    Parasite Infection
    Decoquinate is an orally active, selective inhibitor of the mitochondrial bc1 complex, targeting Eimeria spp. sporozoites and first generation schizonts, and Plasmodium spp. Decoquinate inhibits electron transfer by competitively binding to the mitochondrial cytochrome b system, blocking the parasite's energy metabolism, thereby inhibiting its development and reproduction. Decoquinate has significant anticoccidial activity, preventing intestinal damage and improving host growth performance, and also has inhibitory effects on the liver and blood stages of Plasmodium. Decoquinate is mainly used in veterinary research to prevent and treat coccidiosis in ruminants and poultry .
    Decoquinate
  • HY-101981S3

    5'-​Uridylic acid-13C9,15N2 dilithium

    Isotope-Labeled Compounds Endogenous Metabolite Apoptosis Potassium Channel Cholinesterase (ChE) Cardiovascular Disease Metabolic Disease
    Uridine 5'-monophosphate- 13C9, 15N2 (5'- Uridylic acid- 13C9, 15N2) dilithium is 13C and 15N-labeled Uridine 5'-monophosphate (HY-101981). Uridine 5'-monophosphate (5'-Uridylic acid) is an orally active mitochondrial ATP-dependent potassium channel activator that has a protective effect on the heart. Uridine 5'-monophosphate can promote the synthesis of CDP-choline and induce apoptosis in intestinal epithelial cells, which is beneficial for gut development and reduces diarrhea .
    Uridine 5'-monophosphate-13C9,15N2 dilithium
  • HY-101981S1

    5'-​Uridylic acid-15N2,d11 dilithium

    Isotope-Labeled Compounds Endogenous Metabolite Apoptosis Potassium Channel Cholinesterase (ChE) Cardiovascular Disease Metabolic Disease
    Uridine 5'-monophosphate- 15N2,d11 (5'- Uridylic acid- 15N2,d11) dilithium is deuterium and 15N labeled Uridine 5'-monophosphate (HY-101981). Uridine 5'-monophosphate (5'-Uridylic acid) is an orally active mitochondrial ATP-dependent potassium channel activator that has a protective effect on the heart. Uridine 5'-monophosphate can promote the synthesis of CDP-choline and induce apoptosis in intestinal epithelial cells, which is beneficial for gut development and reduces diarrhea .
    Uridine 5'-monophosphate-15N2,d11 dilithium
  • HY-W011927

    Bisphenol S; Bis(4-hydroxyphenyl) sulfone

    Estrogen Receptor/ERR Histone Methyltransferase Thyroid Hormone Receptor PI3K Akt mTOR Androgen Receptor Cardiovascular Disease Metabolic Disease Inflammation/Immunology Endocrinology Cancer
    4,4'-Sulfonyldiphenol (Bisphenol S; Bis(4-hydroxyphenyl) sulfone), a substitute for Bisphenol A (HY-18260), is widely used in industrial and consumer products. 4,4'-Sulfonyldiphenol is an oally ative estrogen receptor (ER) agonist and can competitively bind to thyroid hormone receptors (TR) with IC50 values for TRα and TRβ are 2650 μM and 2294 μM respectively, thereby affecting breast development and reducing the expression of androgen receptor (AR) in fetal testes. 4,4'-Sulfonyldiphenol promotes the progression of glioblastoma by upregulating the EZH2 mediated PI3K/AKT/mTOR pathway. Under chronic exposure, 4,4'-Sulfonyldiphenol can cause significant lipid deposition and dyslipidemia in the mouse liver by upregulating JunB and Atf3, and has a role in causing obesity at low doses. 4,4'-Sulfonyldiphenol induces intestinal inflammation by altering the intestinal microbiome. 4,4'-Sulfonyldiphenol accelerates the progression of atherosclerosis in zebrafish embryo larvae .
    4,4'-Sulfonyldiphenol
  • HY-168168

    Endogenous Metabolite Metabolic Disease
    (5aS,6R,6aR)-MK-8666 is a selective GPR40 agonist with activity in promoting fatty acid-induced insulin secretion in pancreatic β cells and intestinal enteroendocrine cells. (5aS,6R,6aR)-MK-8666 has been studied for the inhibition of type 2 diabetes and has shown significant blood glucose lowering effects. Although (5aS,6R,6aR)-MK-8666 is considered to have potential inhibitory advantages, its development was stopped in Phase I clinical trials due to liver safety issues .
    (5aS,6R,6aR)-MK-8666
  • HY-W127512
    5β-Cholanic acid
    1 Publications Verification

    Drug Intermediate Others
    5β-Cholanic acid is a hydrophobic modifier used to modify polymer carriers. 5β-Cholanic acid can improve the acid stability, cell penetration efficiency and drug sustained release ability of nanocarriers, and optimize the oral effectiveness of delivered molecules. 5β-Cholanic acid can covalently bind to Glycol chitosan (GC) to form a GC-CA conjugate, which optimizes the hydrophobic anchoring ability of nanoparticles and enables them to be stably adsorbed on the surface of PLGA nanoparticles. Such nanoparticles can resist dissociation in the gastric acid environment and maintain positive charge to enhance endocytic uptake by intestinal epithelial cells (such as Caco-2 cells). 5β-Cholanic acid can be used in the development of drug delivery systems .
    5β-Cholanic acid
  • HY-W127512R

    Drug Intermediate Others
    5β-Cholanic acid is a hydrophobic modifier used to modify polymer carriers. 5β-Cholanic acid can improve the acid stability, cell penetration efficiency and drug sustained release ability of nanocarriers, and optimize the oral effectiveness of delivered molecules. 5β-Cholanic acid can covalently bind to Glycol chitosan (GC) to form a GC-CA conjugate, which optimizes the hydrophobic anchoring ability of nanoparticles and enables them to be stably adsorbed on the surface of PLGA nanoparticles. Such nanoparticles can resist dissociation in the gastric acid environment and maintain positive charge to enhance endocytic uptake by intestinal epithelial cells (such as Caco-2 cells). 5β-Cholanic acid can be used in the development of drug delivery systems .
    5β-Cholanic acid (Standard)
  • HY-W011927R

    Bisphenol S (Standard); Bis(4-hydroxyphenyl) sulfone (Standard)

    Reference Standards Estrogen Receptor/ERR Histone Methyltransferase Thyroid Hormone Receptor PI3K Akt mTOR Androgen Receptor Cardiovascular Disease Metabolic Disease Inflammation/Immunology Endocrinology Cancer
    4,4'-Sulfonyldiphenol (Bisphenol S; Bis(4-hydroxyphenyl) sulfone) (Standard) is the analytical standard of 4,4'-Sulfonyldiphenol (HY-W011927). This product is intended for research and analytical applications. 4,4'-Sulfonyldiphenol, a substitute for Bisphenol A (HY-18260), is widely used in industrial and consumer products. 4,4'-Sulfonyldiphenol is an estrogen receptor (ER) agonist and can competitively bind to thyroid hormone receptors (TR) with IC50 values for TRα and TRβ are 2650 μM and 2294 μM respectively, thereby affecting breast development and reducing the expression of androgen receptor (AR) in fetal testes. 4,4'-Sulfonyldiphenol promotes the progression of glioblastoma by upregulating the EZH2 mediated PI3K/AKT/mTOR pathway. Under chronic exposure, 4,4'-Sulfonyldiphenol can cause significant lipid deposition and dyslipidemia in the mouse liver by upregulating JunB and Atf3, and has a role in causing obesity at low doses. 4,4'-Sulfonyldiphenol induces intestinal inflammation by altering the intestinal microbiome. 4,4'-Sulfonyldiphenol accelerates the progression of atherosclerosis in zebrafish embryo larvae.
    4,4'-Sulfonyldiphenol (Standard)
  • HY-W011927S
    4,4'-Sulfonyldiphenol-d8
    1 Publications Verification

    Bisphenol S (4,4'-Sulfonyldiphenol)-d8

    Isotope-Labeled Compounds Estrogen Receptor/ERR Histone Methyltransferase Thyroid Hormone Receptor PI3K Akt mTOR Androgen Receptor Cardiovascular Disease Metabolic Disease Inflammation/Immunology Endocrinology Cancer
    4,4'-Sulfonyldiphenol-d8 (Bisphenol S (4,4'-Sulfonyldiphenol)-d8) is the deuterium labeled 4,4'-Sulfonyldiphenol (HY-W011927).4,4'-Sulfonyldiphenol (Bisphenol S; Bis(4-hydroxyphenyl) sulfone), a substitute for Bisphenol A (HY-18260), is widely used in industrial and consumer products. 4,4'-Sulfonyldiphenol is an estrogen receptor (ER) agonist and can competitively bind to thyroid hormone receptors (TR) with IC50 values for TRα and TRβ are 2650 μM and 2294 μM respectively, thereby affecting breast development and reducing the expression of androgen receptor (AR) in fetal testes. 4,4'-Sulfonyldiphenol promotes the progression of glioblastoma by upregulating the EZH2 mediated PI3K/AKT/mTOR pathway. Under chronic exposure, 4,4'-Sulfonyldiphenol can cause significant lipid deposition and dyslipidemia in the mouse liver by upregulating JunB and Atf3, and has a role in causing obesity at low doses. 4,4'-Sulfonyldiphenol induces intestinal inflammation by altering the intestinal microbiome. 4,4'-Sulfonyldiphenol accelerates the progression of atherosclerosis in zebrafish embryo larvae.
    4,4'-Sulfonyldiphenol-d8
  • HY-N0469R

    Reference Standards Endogenous Metabolite Virus Protease HSV Infection Metabolic Disease Inflammation/Immunology
    L-Lysine (Standard) is the analytical standard of L-Lysine. This product is intended for research and analytical applications. L-lysine is an essential amino acid for humans with orally activity. L-lysine can inhibit the occurrence of HSV infections and is used in herpes research. L-lysine increases calcium absorption, reduces diabetes-related diseases, improves gut health, and alleviates pancreatic inflammation. L-lysine can be used in research on metabolism, infection, and inflammation . IC50 & Target:L-lysine (150 mg/kg) promotes, but not initiates, bladder cancer. The administration of L-lysine to rats submitted to colovesical cystoplasty accelerates the development of transitional metaplasia of the intestinal epithelium .
    L-lysine (10 mg/kg) treatment attenuates pancreatic tissue injury induced by L-arginine by inhibiting the release of the inflammatory cytokine IL-6 and enhance antioxidant activity . In Vivo:L-lysine (10?mg/kg, p.o., pre-treated or post-treated, administration duration 15 days) treatment attenuates pancreatic tissue injury induced by L-arginine by inhibiting the release of the inflammatory cytokine IL-6 and enhance antioxidant activity in acute pancreatitis mice model . L-lysine (5 or 10?mg/kg, p.o., 45 days) ameliorates sepsis-induced acute lung injury in a lipopolysaccharide (HY-D1056)-induced mouse model .
    L-Lysine (Standard)

Inquiry Online

Your information is safe with us. * Required Fields.

Salutation

 

Country or Region *

Applicant Name *

 

Organization Name *

Department *

     

Email Address *

 

Product Name *

Cat. No.

 

Requested quantity *

Phone Number *

     

Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: